TY - JOUR
T1 - Trends in cardiogenic shock complicating acute myocardial infarction
AU - Aissaoui, Nadia
AU - Puymirat, Etienne
AU - Delmas, Clément
AU - Ortuno, Sofia
AU - Durand, Eric
AU - Bataille, Vincent
AU - Drouet, Elodie
AU - Bonello, Laurent
AU - Bonnefoy-Cudraz, Eric
AU - Lesmeles, Gilles
AU - Guerot, Emmanuel
AU - Schiele, Francois
AU - Simon, Tabassome
AU - Danchin, Nicolas
N1 - Funding Information:
N.A. received speaker's honoraria from AstraZeneca, Medtronic, Abiomed, and Abott. C.D. received personal fees from Abiomed, Novartis, Abott and research grants from Maquet, Orion Pharma, Térumo. T.S. Simon received speaker's honoraria from AstraZeneca, BMS, Sanofi, Novartis and research grants from AstraZeneca, Daiichi‐Sankyo, Eli‐Lilly, GSK, MSD, Novartis, and Sanofi. N.D. received significant research grants from Pfizer, Sanofi‐Aventis and Servier. The other authors have nothing to disclose. Conflict of interest:
Funding Information:
The FAST-MI 2005 and 2010 registries are the propriety of the French Society of Cardiology and were funded by grants from the following companies: Amgen, AstraZeneca, Bayer, BMS, Daiichi-Sankyo, Eli-Lilly, GSK, MSD, Novartis, Pfizer, Sanofi, and Servier, and by a grant from the French National Health Insurance body (CNAM-TS). Conflict of interest: N.A. received speaker's honoraria from AstraZeneca, Medtronic, Abiomed, and Abott. C.D. received personal fees from Abiomed, Novartis, Abott and research grants from Maquet, Orion Pharma, T?rumo. T.S. Simon received speaker's honoraria from AstraZeneca, BMS, Sanofi, Novartis and research grants from AstraZeneca, Daiichi-Sankyo, Eli-Lilly, GSK, MSD, Novartis, and Sanofi. N.D. received significant research grants from Pfizer, Sanofi-Aventis and Servier. The other authors have nothing to disclose. We are indebted to the patients who accepted to participate and to all physicians who took care of them. We acknowledge the help of ICTA (Fontaine-l?s-Dijon, France), and Axonal (Nanterre, France) for data collection. Our gratitude to the personnel of URCEST (Assistance Publique des H?pitaux de Paris and University Paris 6). Special thanks to Vincent Bataille, PhD, (ADIMEP, Toulouse) for data management, Beno?t Pace (Soci?t? Fran?aise de Cardiologie) who designed the electronic case record form, and to Genevi?ve Mulak, Pharm D. and Nicole Naccache, Pharm D. (Soci?t? Fran?aise de Cardiologie) for their help, and to Elodie Drouet, MSc, who supervised patient follow-up. The FAST-MI 2005 and 2010 registries are the propriety of the French Society of Cardiology and were funded by grants from the following companies: Amgen, AstraZeneca, Bayer, BMS, Daiichi-Sankyo, Eli-Lilly, GSK, MSD, Novartis, Pfizer, Sanofi, and Servier, and by a grant from the French National Health Insurance body (CNAM-TS). Conflict of interest: N.A. received speaker's honoraria from AstraZeneca, Medtronic, Abiomed, and Abott. C.D. received personal fees from Abiomed, Novartis, Abott and research grants from Maquet, Orion Pharma, T?rumo. T.S. Simon received speaker's honoraria from AstraZeneca, BMS, Sanofi, Novartis and research grants from AstraZeneca, Daiichi-Sankyo, Eli-Lilly, GSK, MSD, Novartis, and Sanofi. N.D. received significant research grants from Pfizer, Sanofi-Aventis and Servier. The other authors have nothing to disclose.
Funding Information:
The FAST‐MI 2005 and 2010 registries are the propriety of the French Society of Cardiology and were funded by grants from the following companies: Amgen, AstraZeneca, Bayer, BMS, Daiichi‐Sankyo, Eli‐Lilly, GSK, MSD, Novartis, Pfizer, Sanofi, and Servier, and by a grant from the French National Health Insurance body (CNAM‐TS).
Publisher Copyright:
© 2020 European Society of Cardiology
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Aims: Few studies describe recent changes in the prevalence, management, and outcomes of cardiogenic shock (CS) patients complicating acute myocardial infarction (AMI) in the era of widespread use of invasive strategies. The aim of the present study was to analyse trends observed in CS complicating AMI over the past 10 years, focusing on the timing of CS occurrence (i.e. primary CS, CS on admission vs. secondary CS, CS developed subsequently during hospitalization). Methods and results: Three nationwide French registries conducted and designed to evaluate AMI management and outcomes in ‘real-life’ practice included consecutive AMI patients (n = 9951) admitted to intensive cardiovascular care units (ICCUs) over a 1-month period, 5 years apart. The prevalence of CS complicating AMI decreased from 2005 to 2015: 5.9%, mean age 74.1 ± 12.7 in 2005; 4.0%, mean age 73.9 ± 12.7 in 2010, 2.8%, mean age 71.1 ± 15.0 in 2015 (P ' 0.001). It decreased for both primary (1.8% to 1.0%) and secondary CS (4.1% to 1.8%). The profile of CS patients also changed over time with more patients presenting out-of-hospital cardiac arrest. In both primary and secondary CS, the use of percutaneous coronary intervention increased markedly over time, as did the use of mechanical ventilation and cardiac assist devices. Over the 10-year period, in-hospital mortality remained unchanged for both primary CS (41.8% to 37.8%) or secondary CS (57.3% to 58.8%). However, 1-year mortality decreased in patients with primary CS (from 60% to 37.8%, P = 0.038), and remained unchanged in patients developing secondary CS (from 64.5% to 69.1%, P = 0.731). Conclusion: Cardiogenic shock complicating AMI has become less frequent but, if present, CS, and particularly secondary CS, carries a very high mortality, which has not substantially improved over the past 10 years, in spite of the more frequent use of invasive strategies.
AB - Aims: Few studies describe recent changes in the prevalence, management, and outcomes of cardiogenic shock (CS) patients complicating acute myocardial infarction (AMI) in the era of widespread use of invasive strategies. The aim of the present study was to analyse trends observed in CS complicating AMI over the past 10 years, focusing on the timing of CS occurrence (i.e. primary CS, CS on admission vs. secondary CS, CS developed subsequently during hospitalization). Methods and results: Three nationwide French registries conducted and designed to evaluate AMI management and outcomes in ‘real-life’ practice included consecutive AMI patients (n = 9951) admitted to intensive cardiovascular care units (ICCUs) over a 1-month period, 5 years apart. The prevalence of CS complicating AMI decreased from 2005 to 2015: 5.9%, mean age 74.1 ± 12.7 in 2005; 4.0%, mean age 73.9 ± 12.7 in 2010, 2.8%, mean age 71.1 ± 15.0 in 2015 (P ' 0.001). It decreased for both primary (1.8% to 1.0%) and secondary CS (4.1% to 1.8%). The profile of CS patients also changed over time with more patients presenting out-of-hospital cardiac arrest. In both primary and secondary CS, the use of percutaneous coronary intervention increased markedly over time, as did the use of mechanical ventilation and cardiac assist devices. Over the 10-year period, in-hospital mortality remained unchanged for both primary CS (41.8% to 37.8%) or secondary CS (57.3% to 58.8%). However, 1-year mortality decreased in patients with primary CS (from 60% to 37.8%, P = 0.038), and remained unchanged in patients developing secondary CS (from 64.5% to 69.1%, P = 0.731). Conclusion: Cardiogenic shock complicating AMI has become less frequent but, if present, CS, and particularly secondary CS, carries a very high mortality, which has not substantially improved over the past 10 years, in spite of the more frequent use of invasive strategies.
UR - http://www.scopus.com/inward/record.url?scp=85079892286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079892286&partnerID=8YFLogxK
U2 - 10.1002/ejhf.1750
DO - 10.1002/ejhf.1750
M3 - Article
C2 - 32078218
AN - SCOPUS:85079892286
SN - 1388-9842
VL - 22
SP - 664
EP - 672
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 4
ER -